Thai Noipho/iStock via Getty Images
The annual launch price of novel treatments approved from 2022 to 2024 continued to rise significantly in the U.S., exceeding the rate of inflation and GDP growth, a new report from the drug pricing watchdog, the Institute for Clinical and Economic Review (ICER), indicated on